5-Amino-1MQ vs CJC-1295 (without DAC / Mod GRF 1-29)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

5-Amino-1MQCJC-1295 (without DAC / Mod GRF 1-29)
CategoryPeptidesPeptides
Standard DoseResearch indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.
TimingMorning dosing preferred. Can be taken with or without food.Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.
Cycle Duration8-12 week cycles.12-24 week cycles with 4-8 week breaks.
Evidence Levelanimal_plus_anecdotalmoderate_human
A

5-Amino-1MQ

Peptides

Mechanism

5-Amino-1MQ is a small molecule inhibitor of nicotinamide N-methyltransferase (NNMT), an enzyme that catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to nicotinamide, generating 1-methylnicotinamide (1-MNA). By inhibiting NNMT, 5-Amino-1MQ increases intracellular NAD+ levels, reduces 1-MNA production, suppresses lipogenesis in adipocytes, and modulates the methionine-homocysteine cycle. In vivo, it significantly reduces body weight, white adipose mass, and adipocyte size through enhanced energy expenditure and altered lipid metabolism.

Standard Dosing

Research indicates 50-150 mg daily via oral administration, typically divided into 1-2 doses.

Timing

Morning dosing preferred. Can be taken with or without food.

Cycle Duration

8-12 week cycles.

Side Effects

  • Mild GI discomfort
  • Headache
  • Diarrhea (uncommon)
  • Nausea at higher doses

Contraindications

  • Pregnancy and breastfeeding
  • Severe hepatic impairment
  • Active cancer (NAD+ modulation concern)

Best Stacking Partners

MOTS-cAOD-9604TesofensineSemaglutide

Mechanism

Mod GRF 1-29 (Modified Growth Hormone Releasing Factor, amino acids 1-29) is a truncated and modified GHRH analog that binds to GHRH receptors on anterior pituitary somatotrophs, activating cAMP via Gs protein/adenylate cyclase and mitogen-activated protein kinase pathways. Without the DAC moiety, it has a short half-life of approximately 30 minutes, producing acute GH pulses that more closely mimic natural pulsatile GH secretion. It also stimulates pituitary gene transcription of GH mRNA, preserving endogenous pituitary reserve.

Standard Dosing

Research indicates 100-300 mcg administered 1-3 times daily via subcutaneous injection.

Timing

Best administered at bedtime (primary), upon waking, and/or post-workout. Always on empty stomach — wait 2+ hours after last meal. Avoid carbohydrates 30+ minutes after injection.

Cycle Duration

12-24 week cycles with 4-8 week breaks.

Side Effects

  • Flushing post-injection
  • Head rush
  • Hunger increase
  • Water retention (mild)
  • Tingling in extremities

Contraindications

  • Active cancer
  • Diabetic retinopathy
  • Pregnancy and breastfeeding
  • Intracranial hypertension

Best Stacking Partners

IpamorelinGHRP-2GHRP-6Hexarelin

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →